Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIDIT-II trial of peginterferon alfa-2a plus tenofovir versus peginterferon alfa-2a plus placebo in chronic hepatitis D
2008-005560-13Phase 2Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Jun 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in Chronic Viral Hepatitis B With Delta-Agent and Hepatitis B with Hepatitis Delta (HBV/HDV) comparing Peginterferon alfa-2a plus tenofovir with Peginterferon alfa-2a plus placebo (2 arms). Primary endpoints: Virological efficacy based on HDV RNA and Safety. Started Jun 2009; status: completed.
02
Drugs
peginterferon alfa-2atenofovir
03
Conditions
Chronic Viral Hepatitis B With Delta-AgentHepatitis B with Hepatitis Delta (HBV/HDV)
Beyond the preview
Go deeper on 2008-005560-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005560-13.